iBio Expands Product Development Capacity of cGMP Plant
Marketwired MarketwiredNovember 10, 2016Comment
NEW YORK, NY--(Marketwired - Nov 10, 2016) - iBio, Inc. ( NYSE MKT : IBIO ), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced completion of expanded product development capacity of its subsidiary, iBio CMO LLC, for the production of pharmaceutical proteins in hydroponically-grown green plants. This expansion enables iBio CMO's use of iBio proprietary technologies to conduct concurrent product development work for multiple clients in multiple product classes with time-saving transitions from laboratory-level feasibility and testing through cGMP production of active pharmaceutical ingredients for toxicology studies and phase 1 human clinical trials.
"An important consideration for many of our clients and prospective clients is our ability to save them time during critical stages of their proprietary product development programs," said Dr. Barry Holtz, iBio's senior vice president of product development and manufacturing. "We can provide definitive technical answers faster than conventional mammalian cell-based systems and then move directly into larger scale production. This avoids engineering and reengineering mammalian cell lines and dealing with the scale-up issues associated with traditional CHO cell production."
iBio is currently engaged in development of several vaccine and therapeutic candidates for third party clients and is significantly expanding its commitment to the monoclonal antibody product category. The pilot plant expansion enables the company to remain fully committed to its own proprietary anti-fibrosis therapeutics program while taking on promising programs with quality clients.
